State-of-the-art issues in Hodgkin's lymphoma survivorship Journal Article


Authors: Baxi, S. S.; Matasar, M. J.
Article Title: State-of-the-art issues in Hodgkin's lymphoma survivorship
Abstract: The prognosis of Hodgkin's lymphoma (HL) has markedly improved as management strategies evolved. In the modern era, less than 15% of patients with early-stage, non-bulky HL will relapse, and less than one third of those with advanced disease will relapse. As therapy for HL intensified, and as disease-related outcomes improved, the impact of the late effects of therapy has become increasingly important. There is a growing body of literature describing the late morbidity experienced by survivors of HL, including risks of second primary malignancy, cardiac disease, pulmonary disease, and endocrine dysfunction. Additionally, the impact of disease and treatment on psychosocial function and quality of life has been a subject of investigation, with survivors often suffering from impairment. An understanding of these risks and the management implications inherent to them is central to the care of survivors of HL. © 2010 Springer Science+Business Media, LLC.
Keywords: cancer survival; primary tumor; survival rate; acute granulocytic leukemia; prednisone; review; doxorubicin; advanced cancer; cancer combination chemotherapy; cancer risk; solid tumor; antineoplastic agents; cancer radiotherapy; disease free survival; radiation dose; combined modality therapy; cancer staging; neoplasm staging; sensitivity and specificity; disease association; dacarbazine; quality of life; lung toxicity; breast cancer; etoposide; heart disease; lung disease; antineoplastic combined chemotherapy protocols; morbidity; estrogen; lung cancer; alkylating agent; cyclophosphamide; risk factor; cancer mortality; chlormethine; procarbazine; vinblastine; hodgkin disease; ovary insufficiency; late effects; drug dose escalation; survival time; vincristine sulfate; disease severity; hodgkin's lymphoma; cardiovascular disease; cardiovascular diseases; survivorship; bleomycin; malignant neoplastic disease; cancer relapse; thyroid cancer; neoplasms, second primary; gonadorelin agonist; second cancer; hypothyroidism; employment status; anthracycline; oral contraceptive agent; thyroid hormone; endocrine disease; computed tomographic angiography; multidetector computed tomography; lung diseases; azoospermia; endocrine system diseases
Journal Title: Current Oncology Reports
Volume: 12
Issue: 6
ISSN: 1523-3790
Publisher: Springer  
Date Published: 2010-11-01
Start Page: 366
End Page: 373
Language: English
DOI: 10.1007/s11912-010-0123-2
PUBMED: 20734173
PROVIDER: scopus
DOI/URL:
Notes: --- - "Export Date: 20 April 2011" - "CODEN: CORUA" - "Source: Scopus"
Altmetric Score
MSK Authors
  1. Shrujal S Baxi
    69 Baxi
  2. Matthew J Matasar
    121 Matasar